XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses        
Research and development $ 1,487 $ 1,031 $ 3,951 $ 3,430
General and administrative 1,404 194 3,392 600
Total operating expenses 2,891 1,225 7,343 4,030
Financing expenses (income), net 77 (1) 99 (30)
Net loss for the period $ 2,968 $ 1,224 [1] $ 7,442 $ 4,000
Basic and diluted loss per Ordinary Share [2] $ 0.013 $ 0.009 $ 0.038 $ 0.030
Weighted average number of Ordinary Shares outstanding, basic, and diluted [2] 227,956,060 139,397,366 195,292,384 134,360,798
[1] Number and type of equity instruments reflects the capital of the legal parent (the Company).
[2] Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer’s shareholders in the reverse recapitalization transaction (refer to Note 1).